NetraMark Signs Four New Contracts With a Leading Global Pharmaceutical Company To Enhance Clinical Trial Insights

Core Insights - NetraMark Holdings Inc. has signed four contracts with a leading global pharmaceutical company to provide advanced AI analytics for multiple late-stage clinical studies [1][4] - The proprietary NetraAI platform will be utilized to analyze clinical data from these studies, focusing on identifying patient subpopulations that influence treatment and placebo responses [2][3] Group 1: Contract Details - The contracts represent a significant expansion of the ongoing collaboration between NetraMark and the pharmaceutical company, reflecting continued confidence in NetraMark's technology [3][4] - Each study will leverage the NetraAI system, which is designed to identify high-effect-size subgroups within complex datasets, aligning with FDA expectations for explainable AI in clinical development [3][5] Group 2: Technology Overview - NetraAI is engineered to separate small datasets into explainable and unexplainable subsets, enhancing the accuracy of insights derived from clinical data [5][6] - The technology allows for the analysis of smaller datasets while accurately classifying patients based on their sensitivity to drugs and treatment efficacy [6]